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Background: Bone metastasis (BM) is a frequent complication in 
patients with advanced lung cancer and it causes skeletal-related 
events (SREs). Our study aim is to prospectively investigate the inci-
dence of BM, incidence and types of SRE, and predictive factors of 
BM and SREs.
Methods: Newly diagnosed, advanced non–small-cell lung cancer 
(NSCLC) or small-cell lung cancer (SCLC) patients were enrolled 
into the study. Patients were followed up every 4 weeks to monitor 
the development of SREs. Treatment for lung cancer was performed 
at the discretion of the investigator.
Results: Two hundred seventy-four patients were enrolled in this 
study between April 2007 and December 2009 from 12 institutions. 
Patients included 77 cases of SCLC and 197 of NSCLC (stage IIIB/
IV = 73/124). Median follow-up time was 13.8 months. The inci-
dence of BM at initial diagnosis was 48% in stage IV NSCLC and 
40% in extensive stage (ED)-SCLC. Forty-five percent of patients 
who developed BM had SREs consisting of pathologic fracture 
(4.7%), radiation to bone (15.3%), spinal cord compression (1.1%), 
and hypercalcemia (2.2%). Multivariate analysis revealed that fac-
tors predicting BM are stage IV, performance status 1 or greater and 
higher bone alkaline phosphatase in NSCLC patients, higher lactate 
dehydrogenase, and lower parathyroid hormone–related peptide in 
SCLC patients. Factors predicting SREs were stage IV, age 64 or 
younger, and lower albumin in NSCLC patients. Multivariate analy-
sis of SRE was not performed for SCLC because of the small number 
of events.
Conclusion: Predictive factors should be taken into consideration in 
future randomized studies evaluating BM and SREs.
Key Words: Bone metastasis, Skeletal-related event, Lung cancer, 
Predictive factor, Prospective study.
(J Thorac Oncol. 2014;9: 231–238)
Although the overall incidence of bone metastasis (BM) is unknown, BMs are a frequent complication in patients 
with advanced cancer. The most common human cancers such 
as breast, prostate, and lung have a great avidity for bone, 
leading to painful skeletal symptoms. How long patients live 
with a tumor is likely to influence whether BMs will occur. 
For example, in patients who quickly die of cancer because 
of an aggressively growing primary tumor, BMs will be rela-
tively uncommon, simply because they have not adequate time 
to develop. This in no way implies that the tumor cells lacked 
the potential to grow in bone.1,2 In the case of advanced non–
small-cell lung cancer (NSCLC), the median survival time 
(MST) has increased from 8 to 12 months to 15 to 17 months, 
during the past 10 years.3–6 Furthermore, when stage IIIB or 
stage IV NSCLC patients harboring a sensitive epidermal 
growth factor receptor (EGFR) gene mutation were treated 
with gefitinib, MST lengthened to 21.6 to 38.8 months.7–9 On 
the other hand, for patients in limited stage (LD) small-cell 
lung cancer (SCLC), the MST is approximately 2 years.10,11 
For patients with extensive stage (ED) SCLC, survival is 
much more limited, ranging from 9.3 to 12.8 months.12,13 
Accordingly, the chance of developing BM has increased, 
both in advanced NSCLC and LD-SCLC.
BMs can be associated with skeletal-related events 
(SREs), which include pathologic fracture, the need for sur-
gery or radiation to bone, spinal cord compression, and hyper-
calcemia of malignancy (HCM).14–16 Because patient quality 
of life (QOL) deteriorates tremendously once SREs develop, 
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it is important for investigators to treat patients with BM with 
an appropriate treatment, as early as possible. To our knowl-
edge, there have been no prospective studies investigating the 
incidence and predictive factors of BM and SREs in patients 
with advanced lung cancer. Accordingly, it is worthwhile to 
investigate how therapeutic interventions such as chemother-
apy, radiotherapy, and bisphosphonate could affect the clinical 
course of lung cancer patients with BM and the development 
of SREs. The aim of this study is to prospectively investi-
gate: (1) the incidence of BM at initial diagnosis in patients 
with SCLC and stage IV NSCLC, (2) the time interval for 
the development in BM in patients with SCLC and stage IIIB 
NSCLC who have no BM at initial diagnosis, (3) the time 
interval for the development of SRE from BM, and (4) the 
predictive factors of BM and SRE.
MATERIALS AND METHODS
Study Design
This study is a prospective multicenter cohort study. 
Adult patients (at least 20 years of age) with newly diagnosed 
SCLC in all stages and NSCLC in stage IIIB or stage IV were 
eligible.
All patients were required to have received no prior che-
motherapy or bisphosphonate therapy, and were allowed to 
undergo palliative surgical or radiation treatment for skeletal 
complications before registration. Once patients were enrolled 
into the study, treatment for lung cancer and the use of zole-
dronate were at the discretion of the investigator. Zoledronate 
was administered only after the development of BMs. No 
patients received denosumab during the study period, because 
it had not been approved by the Japanese government. The 
study was approved by the institutional review boards of 
the respective institutions and was conducted in compliance 
with international guidelines regulating patient safety. All 
patients provided written informed consent. QOL assessment 
and other therapeutic factors affecting BM and SREs will be 
reported, separately.
Staging of Lung Cancer and Subsequent  
Follow-Up Schedule
Table 1 shows the study schedule. Before patient enroll-
ment, a complete physical examination was performed and a 
medical history was taken, which included history of SREs, 
antineoplastic history, and Eastern Cooperative Oncology 
Group performance status (PS). Blood chemistry and bone 
turnover markers (parathyroid hormone–related peptide 
[PTHrP], bone alkaline phosphatase [BALP], and urine 
 cross-linked N-telopeptide of type I collagen [NTx]) were 
obtained. Tumor assessment was undertaken using chest and 
abdominal computed tomography (CT), radionuclide bone 
scan, or integrated positron emission tomography (PET)-CT. 
Magnetic resonance imaging or enhanced CT of the brain was 
performed when patients were symptomatic. Bone survey was 
performed before enrollment, with thoracic and lumbar spine 
radiograph, pelvic radiograph, and bone scan or integrated 
PET-CT. When BM was suspected only with bone scan or 
PET-CT, its confirmation with bone magnetic resonance imag-
ing, CT scan, or normal radiograph was mandatory.
After enrollment, tumor assessment, Eastern Cooperative 
Oncology Group PS, and SREs were assessed every 4 weeks. 
Bisphosphonate use, pain, and analgesic scores were recorded 
at each visit, every 4 weeks. Blood chemistry was measured 
at each visit, every 4 weeks. Bone scan or integrated PET-CT 
and skeletal survey were assessed every 6 months. After 12 
months of follow-up, the above-mentioned assessments were 
repeated every 3 months. Patients were closely monitored for 
24 months after enrollment into the study.
TABLE 1.  Examination Schedule
Visit
0 1 2 3 4 5 6 7 8 9–12
Enrollment 1 mo 2 mos 3 mos 4 mos 5 mos 6 mos 9 mos 12 mos 24 mos
Allowance ≤1 mo ±2 wk ±2 wk ±2 wks ±2 wks ±2 wks ±2 wks ±6 wks ±6 wks ±6 wks
Bone scintigram or PET o ★ o Repeat 
between 7 
and 8
Radiograph (DV•L-Spine) o
Chest and abdominal CT o ✩ ✩ ✩ ✩
Patient background o
PS o o o o o o o o o
Blood biochemistry o o o o o o o o o
Bone marker (blood and urine) o
Bone metastasis o o o o o o o o o
Metastasis extrabone o o o o o o o o o
Bisphosphonate o o o o o o o o o
Bone pain o o o o o o o o o
Analgesic use o o o o o o o o o
SRE o o o o o o o o o
QOL•ADL o ✩ o
SRE, skeletal-related event; QOL, quality of life; ADL, activity of daily living; PET, positron emission tomography; CT, computed tomography; PS, performance status; 
DV, ; ✩, ±4 wks; ★, ±6 wks.
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Assessment of Outcome
SRE was defined as pathologic fracture, spinal cord 
compression, radiation or surgery to bone, or HCM. Fractures 
were identified by two expert radiologists at each institution. 
Spinal cord compression reported by investigators was con-
firmed by a neurologist and an orthopedic surgeon at each 
institution. Radiation to bone was given to control pain, treat 
or prevent pathologic fractures, or treat or prevent spinal cord 
compression. Surgery to bone included procedures to prevent 
imminent fractures or spinal cord compression or to set/stabi-
lize fractures. Hypercalcemia was defined as a serum calcium 
concentration of greater than 11 mg/dl.
Statistical Analyses
The incidence provability rate was estimated for the 
time to the first occurrence of BM from diagnosis of lung 
cancer, and the time to the first occurrence of SREs from 
the diagnosis of lung cancer or from the first occurrence of 
BM, using the Kaplan–Meier method. Predictive factors for 
BMs and SREs were explored with Cox proportional hazard 
regression model for the following: Tumor type (stage IIIB 
NSCLC, stage IV NSCLC, LD-SCLC, and ED-SCLC), sex, 
age (65 or older/64 or younger), PS (PS1 or greater/PS0), 
and bone markers (lactate dehydrogenase [LDH], albumin, 
calcium, PTHrP, BALP, and urine NTx). The results were 
checked for consistency by conducting both a univariate 
Cox regression model, in which each factor was individu-
ally tested as an explanatory variable, and a multivariate Cox 
regression model, in which all variables were entered simul-
taneously into the model. To investigate whether the use of 
a chemotherapeutic agent and bisphosphonate inhibits the 
occurrence of SREs, Cox regression analysis was performed 
using these factors as time-dependent covariates. All analy-
ses used the SAS statistical software package (version 9.1.3; 
SAS Institute, Cary NC).
The main purpose of this study is to survey lung cancer 
patients regarding the timing of elapsed events from onset to 
BM, to SRE, and is not intended as a comparison of treat-
ment methods. Accordingly, the target number of cases was 
not designed for intergroup comparison, but to describe the 
time distribution until BM, search for predictors which affect 
metastasis to bone, describe what kind of SREs occur, and 
examine the effects on QOL, etc. The target number of cases 
was set at 50, as a number of cases for which descriptive sta-
tistics of some accuracy can be calculated, even for patients 
with stage IIIB NSCLC, which is anticipated to have com-
paratively small enrollment, for a total of approximately 400 
cases from the percentage of each cancer type.
RESULTS
Patients
A total of 274 patients with lung cancer were enrolled 
in the study, between April 2008 and December 2009, from 12 
institutions in Japan. Patient demographics and baseline char-
acteristics are shown in Table 2. One hundred  ninety-seven 
patients had NSCLC (stage IIIB, 73; stage IV, 124), and 77 
patients had SCLC (LD, 30; ED, 47). The majority of patients 
were male (70.4%) and the median age was 68 years (range, 
35–89). Ninety percent of patients had good PS (PS = 0, 
27.7%; PS = 1, 62.4%). The number of patients with BM at 
initial diagnosis was 59 (47.6%) in stage IV NSCLC and 19 
(40.4%) in ED-SCLC. Twenty patients of stage IV NSCLC 
(16.1%) and four patients in ED-SCLC (8.5%) already had 
SRE at the time of enrollment. The majority of patients 
(92.3%) were being treated with chemotherapy. The num-
ber of patients who received zoledronate was eight in stage 
IIIB NSCLC, 49 in stage IV NSCLC, two in LD-SCLC, and 
four in ED-SCLC after the development of BM during the 
study period. EGFR gene mutations were analyzed only in 92 
(46.7%) of 197 NSCLC patients because it was not routinely 
tested during this period. Among these, 38 patients (19.3%) 
had EGFR gene mutations and 30 patients (15.2%) had active 
mutations (L858R or exon 19 deletion). Nine of 30 patients 
were treated with EGFR tyrosine kinase inhibitor (TKI) 
during the first regimen, 19 during the second regimen, and 
two during the third regimen. Eighteen patients (9.2%) were 
not treated with chemotherapy at all. One hundred fifty-two 
patients (77.2%) were treated with some kind of chemother-
apy within 30 days of enrollment. The other patients (13.6%) 
were treated with chemotherapy after 31 days of enrollment.
During the treatment of SCLC, three patients (3.9%) 
were not treated with any kind of chemotherapy, 68 (88.3%) 
patients were treated with some kind of chemotherapy within 
30 days of enrollment, whereas six patients (7.8%) were 
treated with chemotherapy after 31 days of enrollment. The 
number of patients with platinum plus CPT-11 and platinum 
and etoposide in the first regimen were 19 (24.7%) and 40 
(51.9%), respectively. The median follow-up duration was 
13.8 months (range, 0–28.5 months).
Time Interval of Development of BM and SREs
The incidence of BM and SREs at enrollment and dur-
ing follow-up is presented in Figure 1 and Table 3. Among 
274 lung cancer patients, BM was detected in 78 patients 
(28.5%) at enrollment and in another 34 patients (12.4%) dur-
ing follow-up. SREs were reported in 24 patients (8.8%) at 
the time of enrollment and in another 26 patients (9.5%) dur-
ing follow-up. Total number of patients who developed SREs 
was 52 (19.0%). The type of SRE was pathologic fracture in 
14 (5.1%), radiation to bone in 45 (16.4%), spinal cord com-
pression in three (1.1%), and HCM in six (2.2%). The median 
time to BM from diagnosis of lung cancer and to SRE from 
BM was 19.0 months (95% confidence interval [CI], 10.7 to 
not reached) and 9.5 months (95% CI, 5.1–16.9), respectively 
(Fig. 2A and C). However, the median time to SRE from diag-
nosis of lung cancer was not reached (Fig. 2B).
Predictive Factors of BM and SREs
We performed subgroup analysis by separating NSCLC 
and SCLC because their biological characteristics and clinical 
behavior differ. To identify the predictive factors of BM and 
SREs, Cox proportional hazard regression analysis was per-
formed using stage (stage IIIB and stage IV in case of NSCLC, 
and ED and LD in case of SCLC), sex, age, PS, LDH, albumin, 
calcium, PTHrP, BALP, NTx, and treatment (chemotherapy 
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and EGFR-TKI in case of NSCLC, chemotherapy and first-line 
platinum + etoposide or first-line platinum and CPT in case 
of SCLC) (Table 4). The multivariate analysis of the NSCLC 
patients demonstrated that stage IV (hazard ratio [HR] = 7.62; 
95% CI, 3.76–15.46; p < 0.001), PS 1 or greater (HR = 1.82; 
95% CI, 1.01–3.29; p = 0.046), and higher serum BALP level 
(HR = 10.36; 95% CI, 2.35–45.78; p = 0.002) were signifi-
cant predictive factors for BM (Table 4). However, neither 
chemotherapy (HR = 0.51; 95% CI, 0.22–1.20; p = 0.125) 
nor EGFR-TKI (HR = 1.69; 95% CI, 0.76–3.75; p = 0.196) 
were predictive factors. The multivariate analysis of the SCLC 
patients revealed that ED stage (HR = 6.11; 95% CI, 1.69–
22.05; p = 0.006), higher serum LDH at baseline (HR = 9.14; 
95% CI, 1.51–55.14; p = 0.016), and higher serum PTHrP at 
baseline (HR = 0.38; 95% CI, 0.15–0.99; p = 0.048) were sig-
nificant predictive factors, but chemotherapy (HR = 0.52; 95% 
CI, 0.14–1.87; p = 0.340) and first-line use of platinum + eto-
poside or platinum + CPT (HR = 0.44; 95% CI, 0.14–1.40; 
p = 0.165) were not predictive factors.
Regarding SREs, multivariate analysis of NSCLC 
patients demonstrated that stage IV (HR = 5.58; 95% CI, 
2.21–14.10; p < 0.001), age 65 or older (HR = 0.50; 95% 
CI, 0.26–0.96; p = 0.038), and zoledronate use after BM 
(HR = 2.64; 95% CI, 1.25–5.57; p = 0.011) were predictive 
factors for SREs (Table 5). As for SCLC patients, multivariate 
analysis was not performed because of the small number of 
SRE events (only 9 events).
DISCUSSION
According to several studies published before 1991, 
the incidence of BM in NSCLC, as detected by bone scans, 
is between 8% and 34%, with a mean of 20%.17 More 
recent reviews have reported incidences of 24% and 30% in 
American and Japanese patient populations, respectively.18,19 
Moreover, in retrospectively analyzed studies, the incidence of 
BM in patients with stage IV NSCLC was 41% to 54.8%.19,20 
Our prospective study demonstrated that the incidence of BM 
in stage IV NSCLC and ED-SCLC was 46.7% and 40.4%, 
respectively. As newer imaging modalities such as PET and 
bone scan have been developed, the incidence of BM may 
have increased.21,22 However, it has been reported that the 
accuracies of PET and bone scan are 94% and 85% (p < 0.05), 
the sensitivity values were 91% and 75%, and the specificity 
values were 96% and 95%, respectively.22
The frequency of SREs among 274 patients in the 
current prospective study was in the order of frequency, 
TABLE 2.  Patient Characteristics
NSCLC SCLC
TotalStage IIIB Stage IV LD ED
N 73 124 30 47 274
Sex (male/female) 57/16 79/45 18/12 39/8 193/81
Age (median [range]) 69.0 [35–86] 67.0 [41–89] 69.0 [53–80] 68.0 [45–82] 68.0 [35–89]
PS (ECOG)
  0 22 (30.1) 31 (25.0) 23 (29.9) 11 (23.4) 76 (27.7)
  1 43 (58.9) 82 (66.1) 46 (59.7) 30 (63.8) 171 (62.4)
  2 7 (9.6) 8 (6.5) 8 (10.4) 6 (12.89) 23 (8.4)
  ≥3 1 (1.4) 3 (2.4) 0 (0) 0 (0) 4 (1.5)
Bone metastasis
  − 73 (100.0) 65 (52.4) 30 (100) 28 (59.6) 196 (71.5)
  + 0 59 (47.6) 0 (0) 19 (40.4) 78 (28.5)
SRE
  − 73 (100.0) 104 (83.9) 30 (100) 43 (91.5) 250 (91.2)
  + 0 20 (16.1) 0 (0) 4 (8.5) 24 (8.8)
Chemotherapy
  − 9 (12.3) 9 (7.3) 1 (2.1) 2 (6.7) 21 (7.7)
  ≤30 days 54 (74.0) 98 (79.0) 41 (87.2) 27 (90.0) 220 (80.3)
  >30 days 10 (13.7) 17 (13.7) 5 (10.6) 1 (3.3) 33 (12.0)
EGFR mutation
  + 10 (13.7) 28 (22.5) 1 (3.3) 0 (0.0) 39 (14.2)
  − 16 (21.9) 44 (35.5) 1 (3.3) 2 (4.3) 63 (23.0)
  NT 47 (64.4) 52 (42) 28 (93.6) 45 (95.7) 172 (62.8)
Zoledronatea
  + 8 (11.0) 49 (39.5) 4 (8.5) 2 (6.7) 63 (23.0)
  − 65 (89.0) 75 (60.5) 43 (91.5) 28 (93.3) 211 (77.0)
aZoledronate was administered after development of bone metastasis.
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; LD, limited disease; ED, extensive disease; PS, performance status; ECOG, Eastern Cooperative Oncology 
Group; SRE, skeletal-related event; EGFR, epidermal growth factor receptor; NT, not tested.
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radiation to bone (15.7%), pathologic fracture (4.7%), HCM 
(2.2%), and spinal cord compression (1.1%). Because spi-
nal cord compression is considered an oncologic emergency, 
it requires urgent evaluation and treatment with corticoste-
roids and either radiotherapy or surgical decompression. 
Fortunately, we were able to reduce the incidence of spinal 
cord compression, as much as possible, because of close 
monitoring and appropriate treatment. A prospective study 
of 250 patients with a variety of solid tumors (120 of whom 
had NSCLC) complicated with BM found that the incidence 
of SRE was radiation to bone in 32%, pathologic fracture in 
21%, surgery to bone in 4%, spinal cord compression in 4%, 
and HCM in 3% when patients were not treated prophylacti-
cally with zoledronate.15 In a retrospective review of Japanese 
patients with NSCLC, among 135 stage IV patients, the most 
common SREs were the need for radiotherapy in 34.3% and 
hypercalcemia in 20%.19
Another retrospective study of 196 NSCLC patients 
with BM revealed that 47 of 110 patients without initial 
SRE eventually experienced their first SREs while receiving 
chemotherapy, whereas the accompanying type of SRE was 
radiotherapy in 39, pathologic fracture in 11, surgery to bone 
in six, and spinal cord compression in four patients.23
The median time to BM from diagnosis of lung cancer 
and to SREs from BM in our study was 19.0 and 9.5 months, 
respectively. To our knowledge, there seems to be no single 
prospective study which reports the interval to BM from diag-
nosis of stage IIIB NSCLC or LD-SCLC. Our result may be 
useful in future trials to prevent BM from lung cancer with 
bisphosphonate or denosumab, regarding the initiation of 
treatment. The median interval to SRE from BM was 9.5 
months, compared with 171 days for NSCLC patients treated 
with 4 mg of zoledronate.15 In a randomized phase III study 
comparing zoledronate with denosumab in the treatment of 
BMs in patients with advanced cancer (excluding breast and 
prostate cancer) or multiple myeloma, the median time to 
first on-study SRE was 20.6 months for denosumab and 16.3 
months for zoledronate. The effect of denosumab on time to 
first on-study SRE relative to zoledronate by tumor stratifica-
tion factors resulted in an HR of 0.84 for NSCLC (95% CI, 
0.64 to 1.10; p = 0.20).16 However, a direct comparison is not 
possible, as all of the patients in our study were not treated with 
zoledronate or denosumab, and were also treated with various 
types of anticancer drugs, including EGFR-TKIs, which were 
quite effective in EGFR mutation–positive patients.8,9
We evaluated the predictive factors of BM via mul-
tiple regression analysis separately in patients with SCLC 
and patients with NSCLC, because their biologic character-
istics and clinical behavior differ. In case of NSCLC, stage 
IV (HR = 7.62; p < 0.001), PS 1 or greater at enrollment 
(HR = 1.82; p = 0.046), and high serum BALP at baseline (HR 
=10.36; p = 0.002) were found to be positive predictive fac-
tors. Two factors, excluding BALP, represent the tumor burden 
at the time of diagnosis of lung cancer. Therefore, the chance 
of developing BM increases with tumor progression. BALP 
has been investigated as a bone formation marker, but their 
association with clinical characteristics seems to vary depend-
ing on the tumor type, the nature of the BMs, and the effects of 
treatment. BALP measured in our study may represent active 
bone turnover as a result of subclinical metastasis to bone. 
Unexpectedly, EGFR-TKI treatment was not a negative predic-
tive marker of BM. This may be related to the small number of 
active EGFR mutations (30 patients, 15.2%) and the fact that 
that most patients were treated with EGFR-TKI as a second- 
or third-line regimen (21 patients, 70%) instead of a first-line 
regimen. In SCLC, ED at enrollment (HR = 6.11; p = 0.006), 
higher serum LDH at baseline (HR = 9.14; p = 0.016), and 
higher serum PTHrP at baseline (HR = 0.38; p = 0.048) were 
found to be predictive factors. The former two factors repre-
sent the tumor burden at the time of diagnosis of lung cancer 
as in NSCLC while increasing the chance to develop BM. The 
reason why the higher serum PTHrP at baseline was a nega-
tive predictive factor of BM was not clear, but it may be acting 
FIg. 1. A, Time to bone metastasis from diagnosis of lung 
cancer. B, Time to SRE from diagnosis of lung cancer. C, Time 
to SRE from bone metastasis. SRE, skeletal-related event.
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as a nonfunctioning tumor marker. A first-line regimen with 
platinum + CPT-11 or platinum + etoposide tended to be a 
negative predictive factor of BM (HR = 0.44; p = 0.165) but 
did not reach a significant level, probably because of the small 
sample size.
Another multiple regression analysis evaluating the 
predictive factors of SREs from initial documentation of BM 
demonstrated that stage IV NSCLC (HR = 5.58; p < 0.001) 
and zoledronate use after BM were positive factors, whereas 
age 65 or older (HR = 0.50; p = 0.038) was a negative predic-
tive factor for SRE in NSCLC. Multiple regression analysis 
was not performed for SCLC, because the number of patients 
with SREs was only nine and all SREs occurred in ED-SCLC. 
The reason why an age of more than 65 years in NSCLC 
was a negative predictive factor for SREs is not clear in our 
study. This might be related to the physical activity of younger 
patients, as they enjoyed moving, without pain or limita-
tion, and needed to receive radiation therapy more frequently 
than elder patients. Otherwise, older patients might have 
undergone single-agent chemotherapy for longer periods, or 
received molecular-targeted agents more often than younger 
patients. These factors need to be elucidated in a future trial. 
Surprisingly, zoledronate use after BM was a positive predic-
tive factor of SREs. This may be because of the fact that zole-
dronate was used at the discretion of the investigators, and that 
they tended not to administer zoledronate at an early stage, 
but at a progressive stage of BM (bias due to the treatment by 
indication).
Serum albumin was a marginally significant negative 
predictive factor of SRE (HR = 0.59; p = 0.070) by multi-
variate analysis. High serum albumin reflects that patients 
have a good appetite, and can maintain good general condi-
tion, such as body weight. These two factors are also known 
as a good prognostic factor.26–28 In contrast to other reports, 
NTx was not a predictive factor of SRE (p = 0.758) in our 
study.29,30 Brown et al.29 reported a statistically significant cor-
relation between N-telopeptide levels at baseline and a range 
of skeletal complications in 121  bisphosphonate-treated 
patients with breast or prostate cancer with BM. Their defi-
nition of SRE was radiotherapy to bone, hypercalcemia, 
spinal cord compression, pathological fracture, surgery to 
bone, hospital admissions for control of bone pain, and/or 
TABLE 4.  Cox Regression Analysis for Bone Metastasis Incidence (Multivariable Analysis)
Factor
NSCLC SCLC
HR (95% CI) p HR (95% CI) p
NSCLC (stage IV/stage IIIB) 7.62 (3.76–15.46) <0.001
SCLC (ED/LD) 6.11 (1.69–22.05) 0.006
Sex (female/male) 1.02 (0.62–1.66) 0.952 0.90 (0.27–3.03) 0.875
Age (≥65/≤64) 0.69 (0.43–1.11) 0.124 0.74 (0.25–2.21) 9.585
PS (≥1/0) 1.82 (1.01–3.29) 0.046 1.87 (0.61–5.78) 0.276
LDH (1000 U) 1.07 (0.35–3.26) 0.911 9.14 (1.51–55.14) 0.016
Alb (g/dl) 0.82 (0.54–1.25) 0.362 0.70 (0.24–2.05) 0.513
Ca (mg/dl) 0.84 (0.60–1.16) 0.291 0.93 (0.54–1.60) 0.796
PTHrP (pmol/liter) 0.92 (0.76–1.11) 0.388 0.38 (0.15–0.99) 0.048
BALP (100 U/liter) 10.36 (2.35–45.78) 0.002 1.56 (0.60–4.05) 0.363
NTx (1000 nmol BCE/mmol CRE 0.67 (0.21–2.13) 0.499 0.29 (0.02–4.53) 0.374
Chemotherapy (yes/no) 0.51 (0.22–1.20) 0.125 0.52 (0.14–1.97) 0.340
EGFR-TKI (yes/no) 1.69 (0.76–3.75) 0.196
First-line Plat + etoposide or Plat + CPT/other 0.44 (0.14–1.40) 0.165
HR, hazard ratio; CI, confidence interval; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; ED, extensive disease; LD; limited disease, PS, performance status; 
Alb, albumin; PTHrP, parathyroid hormone–related peptide; BALP, bone alkaline phosphatase; NTx, cross-linked N-telopeptide of type 1 collagen; EGFR-TKI, epidermal growth factor 
receptor-tyrosine kinase inhibitor; Plat, platinum; LDH, lactate dehydrogenase; BCE, ; CRE, ; CPT,.
TABLE 3.  Incidence and Type of SREs (N = 274)
All SREs New SREs during Follow-Up Total
n % n % N %
Any SRE 24 8.8 26 9.5 50 18.2
  Pathologic fracture 9 3.3 4 1.5 13 4.7
  Radiation to bone lesion 22 8 21 7.7 43 15.7
  Surgery to bone 0 0 0 0 0 0
  Spinal cord compression 2 0.7 1 0.4 3 1.1
  Hypercalcemia of malignancy 1 0.4 5 1.8 6 2.2
SRE, skeletal-related event.
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death due to metastatic bone disease. The total number of 
SREs was 111 in 121 patients during 6 months. In another 
report, which focused on metastatic NSCLC without zole-
dronate therapy, high NTx level at baseline was associated 
with an increased rate of first SRE, and this increased rate 
was maintained throughout the study period. Overall, there 
were a total of 110 SREs in 115 patients during 21 months.30 
However, there were only 50 SREs among 111 lung cancer 
patients with BM over a median follow-up duration of 13.8 
months, and the number of SREs was relatively low in the 
current study, compared with these two reports. This may be 
the reason why NTx at baseline was not a predictive marker 
of SREs in our study.
CONCLUSIONS
The incidence of BM at initial diagnosis was 48% in 
patients with stage IV NSCLC and 40% in patients with 
ED-SCLC. Forty-six percent of the patients who developed 
BM had SREs at enrollment and during the follow-up period. 
Multivariate analysis revealed that the factors predicting BMs 
were stage IV, PS 1 or greater, higher serum BALP at baseline 
in case of NSCLC and ED, higher serum LDH at baseline, 
and higher serum PTHrP at baseline in case of SCLC, and 
that the factors predicting SRE in NSCLC were stage IV, age 
64 or younger, and zoledronate use after BM. These factors 
should be taken into consideration in future randomized stud-
ies evaluating BM and SREs.
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